N4 Pharma Plc

ONZ

GB00BYW8QM32

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:21 10/05/2024 BST			5-day change	1st Jan Change
0.8 ^GBX	0.00%		0.00%	-5.88%

04-25	N4 Pharma strikes partnership deal for intracellular delivery	AN
04-23	N4 Pharma loss widens but "great optimism" remains	AN

N4 Pharma loss widens but "great optimism" remains

April 23, 2024 at 01:34 pm

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Chief Executive Nigel Theobald says: "2023 was a year of good progress for the company with material advancements in the capabilities of Nuvec both in its ability to dual load and in its potential for oral delivery. We achieved our objective of expanding our portfolio through our interest in Nanogenics which brings us a clear path for taking a product to market and the potential for orphan drug designation."

Current stock price: 0.82 pence, down 2.9% in London on Tuesday

12-month change: down 57%

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Latest news about N4 Pharma Plc

N4 Pharma strikes partnership deal for intracellular delivery	04-25	AN
N4 Pharma loss widens but "great optimism" remains	04-23	AN
N4 Pharma Plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-23	CI
N4 Pharma sees potential in Nuvec delivery method for cancer treatment	04-18	AN
N4 Pharma’s In Vivo Testing Shows Nuvec’s Potential as Oral Delivery System	04-18	MT
N4 Pharma's In-vitro Study Shows Nuvec's Versatility in Inhibiting Cancer Cells	02-15	MT
N4 Pharma shares rise on "encouraging" Nuvec research	02-15	AN
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	02-15	AN
N4 Pharma plc Provides In-Vitro siRNA Update	02-15	CI
N4 Pharma's Nuvec Granted Patent in India	01-19	MT
N4 Pharma gets India patent for medical delivery system	01-19	AN
N4 Pharma touts contract to test glaucoma treatment, ECP105	01-16	AN
N4 Pharma Unit to Prepare Glaucoma Treatment Candidate for Pre-clinical Trials; Shares Plunge	01-16	MT
N4 Pharma Shows Increased Transduction Efficacy for Silica Nanoparticle	01-08	MT
N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8	01-08	AN
N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral Vector	01-08	CI
FTSE 100 outperforms European peers	12-18	AN
N4 Pharma rises on successful results from Nuvec administration	12-18	AN
N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research Work	12-18	CI
N4 Pharma hails "encouraging" siRNA research	12-07	AN
N4 launches investor hub; Capricorn production falls	12-01	AN
Transcript : N4 Pharma Plc, Nanogenics Ltd. - M&A Call	16/10/23
FTSE 100 Closes Thursday Slightly Up as Gilt Yields Weigh on Index	28/09/23	DJ
N4 Pharma shares fall as places shares to fund Nanogenics stake buy	28/09/23	AN
N4 Pharma Buys 71% Stake in Biotechnology Company Nanogenics; Stock Plummets	28/09/23	MT

Chart N4 Pharma Plc

Duration

Period

More charts

Company Profile

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.

Sector

Pharmaceuticals

Calendar

23/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
N4 PHARMA PLC	-5.88%	2.69M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B